The Clinical Spectrum of Multiple Endocrine Neoplasia Type 2A with Cutaneous Lichen Amyloidosis in Ethnic Han Chinese

References

• Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993;363(6428):458–460. doi:10.1038/363458a0.
   PubMed Web of Science ®Google Scholar
• American Thyroid Association Guidelines Task F, Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009;19(6):565–612. doi:10.1089/thy.2008.0403.
   PubMed Web of Science ®Google Scholar
• Elisei R, Alevizaki M, Conte-Devolx B, Frank-Raue K, Leite V, Williams GR. 2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer. Eur Thyroid J 2013;1(4):216–231. doi:10.1159/000346174.
   PubMedGoogle Scholar
• Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015;25(6):567–610. doi:10.1089/thy.2014.0335.
   PubMed Web of Science ®Google Scholar
• Ceccherini I, Romei C, Barone V, Pacini F, Martino E, Loviselli A, et al. Identification of the Cys634–>tyr mutation of the RET proto-oncogene in a pedigree with multiple endocrine neoplasia type 2A and localized cutaneous lichen amyloidosis. J Endocrinol Invest 1994;17(3):201–204. doi:10.1007/BF03347719.
   PubMed Web of Science ®Google Scholar
• Pacini F, Fugazzola L, Bevilacqua G, Viacava P, Nardini V, Martino E. Multiple endocrine neoplasia type 2A and cutaneous lichen amyloidosis: description of a new family. J Endocrinol Invest 1993;16(4):295–296. doi:10.1007/BF03348840.
   PubMed Web of Science ®Google Scholar
• Hofstra RM, Sijmons RH, Stelwagen T, Stulp RP, Kousseff BG, Lips CJ, et al. RET mutation screening in familial cutaneous lichen amyloidosis and in skin amyloidosis associated with multiple endocrine neoplasia. J Invest Dermatol 1996;107(2):215–218. doi:10.1111/1523-1747.ep12329651.
   PubMed Web of Science ®Google Scholar
• Seri M, Celli I, Betsos N, Claudiani F, Camera G, Romeo G. A Cys634Gly substitution of the RET proto-oncogene in a family with recurrence of multiple endocrine neoplasia type 2A and cutaneous lichen amyloidosis. Clin Genet 1997;51(2):86–90. doi:10.1111/j.1399-0004.1997.tb02425.x.
   PubMed Web of Science ®Google Scholar
• Karga HJ, Karayianni MK, Linos DA, Tseleni SC, Karaiskos KD, Papapetrou PD. Germ line mutation analysis in families with multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma. Eur J Endocrinol 1998;139(4):410–415. doi:10.1530/eje.0.1390410.
   PubMed Web of Science ®Google Scholar
• Lemos MC, Carrilho F, Rodrigues FJ, Santos P, Carvalheiro M, Ruas MA, et al. Early onset of medullary thyroid carcinoma in a kindred with multiple endocrine neoplasia type IIA associated with cutaneous lichen amyloidosis. Endocr Pract 2002;8(1):19–22. doi:10.4158/EP.8.1.19.
   PubMedGoogle Scholar
• Vieira AE, Mello MP, Elias LL, Lau IF, Maciel LM, Moreira AC, et al. Molecular and biochemical screening for the diagnosis and management of medullary thyroid carcinoma in multiple endocrine neoplasia type 2A. Horm Metab Res 2002;34(4):202–206. doi:10.1055/s-2002-26712.
   PubMed Web of Science ®Google Scholar
• Verga U, Fugazzola L, Cambiaghi S, Pritelli C, Alessi E, Cortelazzi D, et al. Frequent association between MEN 2A and cutaneous lichen amyloidosis. Clin Endocrinol (Oxf) 2003;59(2):156–161. doi:10.1046/j.1365-2265.2003.01782.x.
   PubMed Web of Science ®Google Scholar
• Ferrer JP, Halperin I, Conget JI, Alsina M, Martinez-Osaba MJ, Palou J, et al. Primary localized cutaneous amyloidosis and familial medullary thyroid carcinoma. Clin Endocrinol (Oxf) 1991;34(6):435–439. doi:10.1111/j.1365-2265.1991.tb00322.x.
   PubMed Web of Science ®Google Scholar
• Abdullah F, Udelsman R. Cutaneous lichen amyloidosis in a family with familial medullary thyroid cancer. Surgery 2004;135(5):563–564. doi:10.1016/S0039-6060(02)21685-2.
   PubMed Web of Science ®Google Scholar
• Gullu S, Gursoy A, Erdogan MF, Dizbaysak S, Erdogan G, Kamel N. Multiple endocrine neoplasia type 2A/localized cutaneous lichen amyloidosis associated with malignant pheochromocytoma and ganglioneuroma. J Endocrinol Invest 2005;28(8):734–737. doi:10.1007/BF03347557.
   PubMed Web of Science ®Google Scholar
• Birla S, Singla R, Sharma A, Tandon N. Rare manifestation of multiple endocrine neoplasia type 2A & cutaneous lichen amyloidosis in a family with RET gene mutation. Indian J Med Res 2014;139(5):779–781.
   PubMedGoogle Scholar
• Scapineli JO, Ceolin L, Punales MK, Dora JM, Maia AL. MEN 2A-related cutaneous lichen amyloidosis: report of three kindred and systematic literature review of clinical, biochemical and molecular characteristics. Fam Cancer 2016;15(4):625–633. doi:10.1007/s10689-016-9892-6.
   PubMed Web of Science ®Google Scholar
• Rothberg AE, Raymond VM, Gruber SB, Sisson J. Familial medullary thyroid carcinoma associated with cutaneous lichen amyloidosis. Thyroid 2009;19(6):651–655. doi:10.1089/thy.2009.0021.
   PubMed Web of Science ®Google Scholar
• Qi XP, Zhao JQ, Chen ZG, Cao JL, Du J, Liu NF, et al. RET mutation p.S891A in a Chinese family with familial medullary thyroid carcinoma and associated cutaneous amyloidosis binding OSMR variant p.G513D. Oncotarget 2015;6(32):33993–34003. doi:10.18632/oncotarget.4992.
   PubMedGoogle Scholar
• Arita K, South AP, Hans-Filho G, Sakuma TH, Lai-Cheong J, Clements S, et al. Oncostatin M receptor-beta mutations underlie familial primary localized cutaneous amyloidosis. Am J Hum Genet 2008;82(1):73–80. doi:10.1016/j.ajhg.2007.09.002.
   PubMed Web of Science ®Google Scholar
• Wang WH, Li LF, Huang ES, Zhang Q, Sun TT, Song QH, et al. A new c.1845A–>T of oncostatin M receptor-beta mutation and slightly enhanced oncostatin M receptor-beta expression in a Chinese family with primary localized cutaneous amyloidosis. Eur J Dermatol 2012;22(1):29–33.
   PubMed Web of Science ®Google Scholar
• Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17(6):1471–1474. doi:10.1245/s10434-010-0985-4.
   PubMed Web of Science ®Google Scholar
• Welander J, Andreasson A, Juhlin CC, Wiseman RW, Backdahl M, Hoog A, et al. Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 2014;99(7):E1352–E1360. doi:10.1210/jc.2013-4375.
   PubMed Web of Science ®Google Scholar
• Ng SB, Turner EH, Robertson PD, Flygare SD, Bigham AW, Lee C, et al. Targeted capture and massively parallel sequencing of 12 human exomes. Nature 2009;461(7261):272–276. doi:10.1038/nature08250.
   PubMed Web of Science ®Google Scholar
• Qi XP, Ma JM, Du ZF, Ying RB, Fei J, Jin HY, et al. RET germline mutations identified by exome sequencing in a Chinese multiple endocrine neoplasia type 2A/familial medullary thyroid carcinoma family. PloS One 2011;6(5):e20353. doi:10.1371/journal.pone.0020353.
   PubMed Web of Science ®Google Scholar
• Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 1996;276(19):1575–1579. doi:10.1001/jama.1996.03540190047028.
   PubMed Web of Science ®Google Scholar
• Anitha B, Mysore V. Lichen amyloidosis: novel treatment with fractional ablative 2,940 nm erbium: YAG laser treatment. J Cutan Aesthet Surg 2012;5(2):141–143. doi:10.4103/0974-2077.99459.
   PubMedGoogle Scholar
• Qi XP, Chen XL, Ma JM, Du ZF, Fei J, Yang CP, et al. RET proto-oncogene genetic screening of families with multiple endocrine neoplasia type 2 optimizes diagnostic and clinical management in China. Thyroid 2012;22(12):1257–1265. doi:10.1089/thy.2012.0134.
   PubMed Web of Science ®Google Scholar
• Qi XP, Zhang RX, Cao JL, Chen ZG, Jin HY, Yang RR. The rare intracellular RET mutation p.S891A in a Chinese Han family with familial medullary thyroid carcinoma. J Biosci 2014;39(3):505–512. doi:10.1007/s12038-014-9428-x.
   PubMed Web of Science ®Google Scholar
• Elisei R, Romei C, Renzini G, Bottici V, Cosci B, Molinaro E, et al. The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center. J Clin Endocrinol Metab 2012;97(2):426–435. doi:10.1210/jc.2011-2046.
   PubMed Web of Science ®Google Scholar
• Machens A, Lorenz K, Dralle H. Individualization of lymph node dissection in RET (rearranged during transfection) carriers at risk for medullary thyroid cancer: value of pretherapeutic calcitonin levels. Ann Surg 2009;250(2):305–310. doi:10.1097/SLA.0b013e3181ae333f.
   PubMed Web of Science ®Google Scholar
• Pelizzo MR, Torresan F, Boschin IM, Nacamulli D, Pennelli G, Barollo S, et al. Early, prophylactic thyroidectomy in hereditary medullary thyroid carcinoma: a 26-year monoinstitutional experience. Am J Clin Oncol 2015;38(5):508–513. doi:10.1097/COC.0b013e3182a78fec.
   PubMed Web of Science ®Google Scholar
• Qi XP, Zhao JQ, Du ZF, Yang RR, Ma JM, Fei J, et al. Prophylactic thyroidectomy for MEN 2-related medullary thyroid carcinoma based on predictive testing for RET proto-oncogene mutation and basal serum calcitonin in China. Eur J Surg Oncol 2013;39(9):1007–1012. doi:10.1016/j.ejso.2013.06.015.
   PubMed Web of Science ®Google Scholar
• Wells SA Jr, Pacini F, Robinson BG, Santoro M. Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. J Clin Endocrinol Metab 2013;98(8):3149–3164. doi:10.1210/jc.2013-1204.
   PubMed Web of Science ®Google Scholar
• Brauckhoff M, Stock K, Stock S, Lorenz K, Sekulla C, Brauckhoff K, et al. Limitations of intraoperative adrenal remnant volume measurement in patients undergoing subtotal adrenalectomy. World J Surg 2008;32(5):863–872. doi:10.1007/s00268-007-9402-y.
   PubMed Web of Science ®Google Scholar
• Castinetti F, Qi XP, Walz MK, Maia AL, Sanso G, Peczkowska M, et al. Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study. Lancet Oncol 2014;15(6):648–655. doi:10.1016/S1470-2045(14)70154-8.
   PubMed Web of Science ®Google Scholar
• Castinetti F, Taieb D, Henry JF, Walz M, Guerin C, Brue T, et al. Management of endocrine disease: outcome of adrenal sparing surgery in heritable pheochromocytoma. Eur J Endocrinol 2016;174(1):R9–18.
   PubMed Web of Science ®Google Scholar
• Walz MK, Peitgen K, Saller B, Giebler RM, Lederbogen S, Nimtz K, et al. Subtotal adrenalectomy by the posterior retroperitoneoscopic approach. World J Surg 1998;22(6):621–626; discussion 6–7. doi:10.1007/s002689900444.
   PubMed Web of Science ®Google Scholar
• Lee DD, Huang JY, Wong CK, Gagel RF, Tsai SF. Genetic heterogeneity of familial primary cutaneous amyloidosis: lack of evidence for linkage with the chromosome 10 pericentromeric region in Chinese families. J Invest Dermatol 1996;107(1):30–33. doi:10.1111/1523-1747.ep12297840.
   PubMed Web of Science ®Google Scholar
• Zuo YG, Song P, Liu Z, Ho MG, Liu YH, Wang HW, et al. Lack of evidence for OSMR and RET gene mutations in a Chinese family with friction melanosis. Clin Exp Dermatol 2010;35(3):282–286. doi:10.1111/j.1365-2230.2009.03426.x.
   PubMed Web of Science ®Google Scholar